We are pleased to invite investors and analysts to participate in our virtual event on Monday, 6 June 2022, highlighting Roche data presented during the congress scientific program from June 3 – 7 2022 and our early-stage oncology portfolio. 16:00 – 17:30 CEST / 15:00 - 16:30 BST 09:00 – 10:30 am CDT / 7:00 – 8:30 am PDT   The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:00 CEST on the day of the event. > click here   Agenda Oncology late-stage portfolio update Elena Bernedo-Arzac, SVP, Oncology Therapeutic Area Head   Key Data at ASCO 2022 - Glofitamab pivotal Ph1b data in 3L+DLBCL - Polivy Asian sub-population data from Ph3 POLARIX in 1L DLBCL Ginna Laporte, MD - VP, Global Head Lymphoma/CLL Clinical Development   Oncology early R&D update Johanna Bendell, M.D., Head of Roche Pharma Research and Early Development (pRED) Oncology Andy Chan, M.D., Ph.D. Senior Vice President, Research Biology, Genentech Research & Early Development (gRED)   Q&A     Access to virtual event (pre-registration required) Please pre-register for our webinar here*.   Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.   A replay of the webcast will be available via > ir.roche.com   *privacy notice   Best regards,
Bruno Eschli Head of Investor Relations	Sabine Borngräber Investor Relations Officer

 

Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com	Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

 

get the latest news and updates to your inbox.